Oculis Q2 2026 loss narrows on CHF 12.1 million warrant valuation gain, FX swing to profit

• Six months ended June 30, 2026 loss narrowed to CHF 38.82 million from CHF 58.59 million, helped by a CHF 6.38 million finance result swing.
• R&D expense edged down 1% to CHF 29.33 million as OCS-01 DIAMOND trial wind-down cut external costs, partly offset by PIONEER-1 ramp.
• G&A rose 42% to CHF 16.49 million, driven mainly by higher share-based compensation from new equity grants and higher grant values.
• Cash, cash equivalents, short-term financial assets totaled CHF 228.3 million at June 30, 2026; operating cash outflow was CHF 35.57 million.
• Raised CHF 47.8 million gross from selling 2,250,000 shares via the ATM program; no FDA filing planned for OCS-01 in DME after Phase 3 endpoints missed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oculis Holding AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-338054), on August 06, 2026, and is solely responsible for the information contained therein.